Nylén Eric
Veterans Affairs Medical Center, Washington, D.C. 20422, USA.
George Washington University School of Medicine, Washington, D.C. 20037, USA.
Rev Cardiovasc Med. 2024 Jul 11;25(7):263. doi: 10.31083/j.rcm2507263. eCollection 2024 Jul.
Physical inactivity and poor cardiorespiratory fitness (CRF) are strongly associated with type 2 diabetes (DM2) and all-cause and cardiovascular morbidity and mortality. Incorporating physical activity promotion in the management of DM2 has been a pivotal approach modulating the underlying pathophysiology of DM2 of increased insulin resistance, endothelial dysfunction, and abnormal mitochondrial function. Although CRF is considered a modifiable risk factor, certain immutable aspects such as age, race, and gender impact CRF status and is the focus of this review. Results show that diabetes has often been considered a disease of premature aging manifested by early onset of macro and microvascular deterioration with underlying negative impact on CRF and influencing next generation. Certain races such as Native Americans and African Americans show reduced baseline CRF and decreased gain in CRF in randomized trials. Moreover, multiple biological gender differences translate to lower baseline CRF and muted responsivity to exercise in women with increased morbidity and mortality. Although factors such as age, race, and sex may not have major impacts on CRF their influence should be considered with the aim of optimizing precision medicine.
身体活动不足和心肺适能差与2型糖尿病(DM2)以及全因和心血管疾病的发病率和死亡率密切相关。在DM2的管理中促进身体活动一直是调节DM2潜在病理生理学的关键方法,DM2的潜在病理生理学包括胰岛素抵抗增加、内皮功能障碍和线粒体功能异常。虽然心肺适能被认为是一个可改变的风险因素,但某些不可改变的因素,如年龄、种族和性别,会影响心肺适能状况,这也是本综述的重点。结果表明,糖尿病常被视为一种早衰疾病,表现为大血管和微血管过早恶化,并对心肺适能产生潜在负面影响,还会影响下一代。某些种族,如美国原住民和非裔美国人,在随机试验中表现出较低的基线心肺适能和心肺适能增加幅度降低。此外,多种生物学上的性别差异导致女性的基线心肺适能较低,对运动的反应性较弱,发病率和死亡率增加。虽然年龄、种族和性别等因素可能对心肺适能没有重大影响,但为了优化精准医学,应考虑它们的影响。
J Am Coll Cardiol. 2022-8-9
Prog Cardiovasc Dis. 2017
J Endocr Soc. 2020-6-7
Eur J Prev Cardiol. 2024-3-4
Int J Environ Res Public Health. 2021-9-29
Front Sports Act Living. 2025-6-26
Rev Cardiovasc Med. 2022-8-10
Nat Commun. 2023-7-3
J Clin Invest. 2023-6-15
Lancet Diabetes Endocrinol. 2023-6
J Am Coll Cardiol. 2022-8-9